参附注射液治疗冠心病临床用药方案实效研究(3)
treatment of coronary heart disease
YANG Jing1， LI Lin2， XIE Yan-ming1*， SHEN Hao1， ZHUANG Yan3
(1.Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences， Beijing 100700， China；
2.School of Statistics， Renmin University of China， Beijing 100872， China；
3.The PLA Navy General Hospital， Beijing 100048， China)
[Abstract] Objective： To understand the clinical circumstances for the use of parenterally administered Shenfu in the treatment of coronary heart disease， in order to provide a reference guide for its clinical use. Method： Information was extracted and summarized on the treatment of coronary heart disease patients， who received parenterally administered Shenfu， from 20 nationwide general hospitals HIS data. Descriptive statistical methods were used to analyze the usage and dosage. Correlation analysis was adopted to analyze information including drug combinations， and outcomes were compared with other combinations. Result： Real world HIS data showed that the drug delivery method for parenterally administered Shenfu was intravenous infusion. Treatment courses were from 3 to7 days， at a dosage of 60 mL. The drug combination was mostly with chemical drugs. The most common combinations were Shenfu plus clopidogrel， aspirin and isosorbide dinitrate. Conclusion： Parenterally administered Shenfu is a common drug used in the treatment of coronary heart disease. Most of the usage was in accordance with instructions. The chemical combination drugs were mainly clopidogrel， aspirin and isosorbide dinitrate.
[Key words] parenterally administered Shenfu； clinical pharmacotherapy； outcomes research
doi：10.4268/cjcmm20131832, http://www.100md.com(杨靖 李霖 谢雁鸣 申浩 庄严)
YANG Jing1， LI Lin2， XIE Yan-ming1*， SHEN Hao1， ZHUANG Yan3
(1.Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences， Beijing 100700， China；
2.School of Statistics， Renmin University of China， Beijing 100872， China；
3.The PLA Navy General Hospital， Beijing 100048， China)
[Abstract] Objective： To understand the clinical circumstances for the use of parenterally administered Shenfu in the treatment of coronary heart disease， in order to provide a reference guide for its clinical use. Method： Information was extracted and summarized on the treatment of coronary heart disease patients， who received parenterally administered Shenfu， from 20 nationwide general hospitals HIS data. Descriptive statistical methods were used to analyze the usage and dosage. Correlation analysis was adopted to analyze information including drug combinations， and outcomes were compared with other combinations. Result： Real world HIS data showed that the drug delivery method for parenterally administered Shenfu was intravenous infusion. Treatment courses were from 3 to7 days， at a dosage of 60 mL. The drug combination was mostly with chemical drugs. The most common combinations were Shenfu plus clopidogrel， aspirin and isosorbide dinitrate. Conclusion： Parenterally administered Shenfu is a common drug used in the treatment of coronary heart disease. Most of the usage was in accordance with instructions. The chemical combination drugs were mainly clopidogrel， aspirin and isosorbide dinitrate.
[Key words] parenterally administered Shenfu； clinical pharmacotherapy； outcomes research
doi：10.4268/cjcmm20131832, http://www.100md.com(杨靖 李霖 谢雁鸣 申浩 庄严)